{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:11:16Z","timestamp":1787019076173,"version":"build-2736575974"},"reference-count":51,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Med Care Res Rev"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>This study examines the impact of legalizing fentanyl test strips (FTSs) on drug-related mortality in the United States from 2018 to 2022. Using a difference-in-differences approach with state-level data, we find that FTS legalization is associated with a significant reduction in drug-overdose deaths. Across the population, FTS legalization corresponds to a 7% decrease in overdose mortality, with an even more pronounced 13.5% reduction among Black individuals. Our analysis employs two-way fixed effects models and triple differences specifications to isolate the effect of FTS legalization from other factors. The results suggest that FTS legalization is particularly effective in reducing unintentional drug-overdose deaths. These findings underscore the potential of FTS as a critical harm reduction tool in addressing the opioid crisis, especially in mitigating racial disparities in overdose mortality. The study provides evidence to support expanding access to FTS as part of comprehensive public health strategies.<\/jats:p>","DOI":"10.1177\/10775587251316919","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:10:02Z","timestamp":1739344202000},"page":"240-251","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of Fentanyl Test Strips as Harm Reduction for Drug-Related Mortality"],"prefix":"10.1177","volume":"82","author":[{"given":"Moiz","family":"Bhai","sequence":"first","affiliation":[{"name":"University of Arkansas at Little Rock, USA"},{"name":"University of Arkansas for Medical Sciences, Little Rock, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-1787","authenticated-orcid":false,"given":"Benjamin J.","family":"McMichael","sequence":"additional","affiliation":[{"name":"The University of Alabama, Tuscaloosa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Ball State University, Muncie, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13675"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/restud\/rdae007"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1257\/pol.20160094"},{"key":"e_1_3_4_5_1","unstructured":"California Department of Public Health. (2024). Fentanyl and fentanyl test strips: Frequently asked questions. Substance and Addiction Prevention Branch California Department of Public Health. https:\/\/www.cdph.ca.gov\/Programs\/CCDPHP\/sapb\/CDPH%20Document%20Library\/FentanylTestStrips_FAQs.pdf"},{"key":"e_1_3_4_6_1","doi-asserted-by":"crossref","unstructured":"Ciccarone D. (2021). The rise of illicit fentanyls stimulants and the fourth wave of the opioid overdose crisis. Current Opinion Psychiatry 34(4) 344\u2013350. https:\/\/doi.org\/10.1097\/YCO.0000000000000717","DOI":"10.1097\/YCO.0000000000000717"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100710"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104241"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109425"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2016.0448"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108350"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1077558719880090"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2024.307845"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16318"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16318"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00119-0"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0276-0"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jeconom.2021.03.014"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102661"},{"issue":"11","key":"e_1_3_4_20_1","article-title":"Implications of increased access to buprenorphine for medical providers in rural areas: A review of the literature and future directions","volume":"13","author":"Gregory H. M.","year":"2021","unstructured":"Gregory H. M., Hill V. M., Parker R. W. (2021). Implications of increased access to buprenorphine for medical providers in rural areas: A review of the literature and future directions. Cureus, 13(11), e19870.","journal-title":"Cureus"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.4321"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100813"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6817a3"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2024.108034"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.1830"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0213-2"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4603(96)00042-1"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.66.4.604"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4603(02)00294-0"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.05.029"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpubeco.2023.104901"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/10775587221126777"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/730381"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.06.038"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.05.004"},{"key":"e_1_3_4_36_1","unstructured":"Network for Public Health Law. (2024 August). Harm reduction and overdose prevention: 50-state survey: Legality of drug checking equipment in the United States. https:\/\/www.networkforphl.org\/"},{"key":"e_1_3_4_37_1","unstructured":"Office of Addiction Services and Supports. (2024). Community Overdose Prevention Education (Project COPE). New York State Office of Addiction Services and Supports. https:\/\/oasas.ny.gov\/projectcope"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103196"},{"key":"e_1_3_4_39_1","doi-asserted-by":"crossref","unstructured":"Patrick S. W. Fry C. E. Jones T. F. Buntin M. B. (2016). Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Affairs 35(7) 1324\u20131332. https:\/\/www.healthaffairs.org\/doi\/full\/10.1377\/hlthaff.2015.1496?casa_token=dQMNWaDi80kAAAAA%3ADhsNWlMPyquVJuJDUC52AlPgCzHGomhOxzVZAb3a-CxFjhuSTWXxgqjEsUXZgHZQqEka-IFuMF8K","DOI":"10.1377\/hlthaff.2015.1496"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.08.007"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/1077558721994994"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.85.8_Pt_1.1059"},{"key":"e_1_3_4_43_1","unstructured":"SAMHSA. (2021 April 7). Federal grantees may now use funds to purchase fentanyl test strips. https:\/\/www.samhsa.gov\/newsroom\/press-announcements\/202104070200"},{"key":"e_1_3_4_44_1","unstructured":"SAMHSA. (2022). Highlights for the 2022 National Survey on Drug Use and Health. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt42731\/2022-nsduh-main-highlights.pdf"},{"key":"e_1_3_4_45_1","unstructured":"SAMHSA. (2024). Fentanyl and xylazine test strips. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/medications-counseling-related-conditions\/fentanyl-xylazine-test-strips"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108019"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2022.10.009"},{"key":"e_1_3_4_48_1","volume-title":"Drug overdose deaths in the United States, 2002-2022","author":"Spencer M. R.","year":"2024","unstructured":"Spencer M. R., Garnett M., Mini\u00f1o A. M. (2024). Drug overdose deaths in the United States, 2002-2022. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics."},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.11.033"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/00221465211067209"},{"key":"e_1_3_4_51_1","unstructured":"WebMD. (2024 May 27). How to find and use fentanyl test strips. https:\/\/www.webmd.com\/mental-health\/addiction\/fentanyl-testing-strips"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13861"}],"updated-by":[{"DOI":"10.1177\/10775587261457313","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000}}],"container-title":["Medical Care Research and Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10775587251316919","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10775587251316919","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10775587251316919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:50:59Z","timestamp":1782733859000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10775587251316919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/10775587251316919"],"URL":"https:\/\/doi.org\/10.1177\/10775587251316919","relation":{},"ISSN":["1077-5587","1552-6801"],"issn-type":[{"value":"1077-5587","type":"print"},{"value":"1552-6801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}